• What is Cardax, Inc.'s stock symbol?

  • Our common stock is currently quoted on the OTCQB, but following our voluntary suspension of Exchange Act reporting in August 2021, we anticipate that our common stock will be quoted on the OTC Pink Open Market, although we can give no assurance that any broker will continue to make a market in our stock.

  • When was Cardax, Inc. incorporated? When did Cardax, Inc. become a public company?

  • May 5, 2006

    Cardax Pharmaceuticals, Inc. ("Holdings") acquired the intellectual property and other assets regarding certain astaxanthin technologies from Hawaii Biotech, Inc., a Delaware corporation ("HBI"), in exchange for shares of common stock of Holdings, shares of preferred stock of Holdings, options to purchase shares of common stock of Holdings and the assumption by Holdings of certain liabilities of HBI.

    May 5, 2006 to May 31, 2013

    Holdings continued the research and development of astaxanthin technologies and related compounds and raised capital primarily through the issuance of debt securities.

    May 31, 2013

    Cardax Pharmaceuticals, Inc. ("Holdings") contributed its assets to Cardax Pharma Inc. ("Pharma") in exchange for all of the capital stock of Pharma and the assumption by Pharma of all of the liabilities of Holdings.

    May 31, 2013 to February 7, 2014

    Pharma continued the business of Holdings including the research and development of nutraceutical and pharmaceutical technologies, including the commercialization of our technologies for products, and raised capital through the offering of senior secured convertible promissory notes.

    January 10, 2014

    We made our first investment in Pharma by purchasing 40% of the Pharma common stock (determined after our purchase of such shares) for shares of our Common Stock.

    February 7, 2014

    We consummated the Merger and will continue the nutraceutical and pharmaceutical business of Pharma.

    In connection with the Merger, we amended and restated our certificate of incorporation and bylaws, in the forms filed herewith as Exhibits 3.1 and 3.2, respectively, and incorporated herein by reference, changed our name from Koffee Korner Inc. to Cardax, Inc., changed our fiscal year end to December 31, and changed the par value of our Common Stock and preferred stock to $0.001 per share.

    Prior to the Merger, we operated under the name of "Koffee Korner"s, Inc." as a single location retailer of specialty coffee located in Houston, Texas. Koffee Korner"s, Inc. was initially formed as a Texas corporation in July 2003 and became a Delaware corporation in January 2012. On the Closing Date, we distributed all of the issued and outstanding shares of Koffee Korner"s Inc., which operated our retail coffee business, to Nazneen D"Silva, in accordance with the terms of the Spin-off Agreement dated as February 7, 2014 (the "Spin-off Agreement"). Under the terms of the Spin-off Agreement, we will be indemnified and held harmless against any and all losses, liabilities, damages and expenses whatsoever as and when incurred arising out of, or based upon, or in connection with our business and the business of Koffee Korner"s Inc. prior to the date of this distribution.

    December 30, 2015

    We consummated the merger (the “Holdings Merger”) of Holdings with and into us. There was not any change to our fully diluted capitalization due to the Holdings Merger.

  • Where is Cardax, Inc. located?

  • Cardax, Inc.
    2800 Woodlawn Drive
    Suite 129
    Honolulu, HI 96822

  • When is Cardax, Inc.'s fiscal year end?

  • December 31st

  • Who is Cardax, Inc.'s transfer agent?

  • VStock Transfer, LLC
    18 Lafayette Place
    Woodmere, NY 11598

  • Who is Cardax, Inc.'s outside legal counsel?

  • Wilson Williams LLC
    43 West 43rd Street
    Suite 130
    New York, NY 10036

  • Who can I contact for general information about Cardax, Inc.?

  • Cardax, Inc.
    Investor Relations
    (808) 457-1400
    investors@cardaxpharma.com